StocksMedium•10 November 2026•
1 min read
Co-Diagnostics Cuts Q3 2026 Operating Expenses by 12% Amid Regulatory Push
Key Facts
1Co-Diagnostics reported Q3 2026 financial results, highlighting a 12% year-over-year decrease in operating expenses.
2The company submitted 510(k) and CLIA Waiver applications to the FDA for its Flu A/B & RSV test on the Co-Dx PCR Pro instrument.
3The company launched integrated cloud and mobile infrastructure in India to support tuberculosis clinical work.
Co-Diagnostics reported its Q3 2026 financial results, highlighted by a 12% year-over-year reduction in operating expenses. According to a company statement via PR Newswire, regulatory 510(k) and CLIA Waiver applications were submitted to the FDA for Flu A/B and RSV tests on the Co-Dx PCR Pro instrument.
The company also launched integrated cloud and mobile infrastructure in India to support tuberculosis clinical work as part of its international expansion strategy. CODX closed at $0.319 on November 9, 2026, having traded between a day high of $0.3448 and a day low of $0.2615 during that session.